



الجامعة السورية الخاصة
SYRIAN PRIVATE UNIVERSITY

DR. NAZIR IBRAHIM

MRCP, HEPATOLOGY & GASTROENTEROLOGY
ASSOCIATE PROFESSOR

www.spu.edu.sy

Liver /internal medicine 2

- ▣ **References :**

- ▣ 1-Davidson English 2014

- ▣ 2- Davidson :Arabic from MOHE

- ▣ 3- Position Paper WHO on viral hepatitis

- ▣ 4- lectures on SPU site

- ▣ 5- extra reading added

- ▣ **Languish :** English

- ▣ **Exam:** MCQ

- ▣ May be added lectures by another professors

First lecture 2019-2020 liver (V.2)

- ▣ Liver disease
 - Introduction
 - Anatomy & physiology
 - Prevalence of liver disease
 - Jaundice
 - LFTs

2/12



LIVE === LIVER

- It was at one time considered the seat of life hence its name ,
- liver the thing we live with

- Ambrose Bierce (1842-1914)


LIVER

- ▣ UNIQUE
- ▣ >500 vital function
- ▣ Holds one pint of blood supply at any given moment(13%)
- ▣ organ that can regenerate itself
- ▣ 1.2 – 1.5kg



منظمة
الصحة العالمية

WHO
Fact Sheet – N° 204 - 2016



130–150 million people have chronic HCV.
(WHO) studies detect
21.3 million carriers in the Middle East



World Health
Organization

May 2016

WHO adopted the first-ever **global hepatitis strategy** with a goal to eliminate viral hepatitis as a public health threat by 2030



**World Health
Organization**

“Unlike most communicable diseases, the absolute burden between 1990 and 2013 increased”

Stanaway and colleagues (2016) ,B&M review



**World Health
Organization**

in North Africa and the Middle East, nearly one million deaths in 2013 due to viral hepatitis.

Stanaway and colleagues (2016)

WHO Goals

Incidence

- lower occurrence of new infection
- %30 2020
- 2030 %80

Death

- %10 2020 lower by
- 65%
- 2030

Diagnosis

90 % of Pts Know about their illness

therapy

%80: 2030



ندوة


التهابات الكبد الفيروسية

LIVER the thing
we LIVE with

مشفى الأسد الجامعي - مدرج الشهيد باسل جافظ الأسد

من 1-3 ايلول 2003

دمشق





التعليمات الناظمة
لتدبير التهاب الكبد /ب/
على المستوى الوطني
Management of Hepatitis B
National Guidelines

نيسان 2009



SWGSVH

مجموعة العمل السورية لدراسة
التهابات الكبد الفيروسيّة



الجمعية السورية
لأمراض الهضم

التعليمات الناظمة
لتدبير التهاب الكبد الفيروسي /ب/
على المستوى الوطني
Management of
Chronic Hepatitis B
National Guidelines

نيسان 2012



التعليمات الناظمة
لتدبير التهاب الكبد /ب/
على المستوى الوطني
Management of Hepatitis B
National Guidelines

نيسان 2009



SWGSVH

مجموعة العمل السورية لدراسة
التهابات الكبد الفيروسيّة



الجمعية السورية
لأمراض الهضم

التعليمات الناظمة
لتدبير التهاب الكبد الفيروسي /ب/
على المستوى الوطني

Management of
Chronic Hepatitis B
National Guidelines

نيسان 2012



التعليمات الناظمة (Guidelines)
لتدبير فرط التوتر البابي
- الدوالي -



Management of Hepatitis B
National Guidelines

التعليمات الناظمة
لتدبير التهاب الكبد /ب/
على المستوى الوطني



الجمعية السورية لدراسة التهابات الكبد الفيروسيّة
أيلول 2003 دمشق



live the thing we live with

Prevalence of Hepatitis B /C in >1million blood donors

	1996	1997	1998	1999	2000	2001	2002
HBsAg	7.01	%5	4.4 %	3.94	3.85	3.6	%3.6
HCV	2.53	1.8	1.7	1.74	1.19	0.74	%0.4

إدارة نقل الدم
2003

Medicine can be notoriously insular



Functional reserve

- ▣ Enormous functional reserve
Surgical removal of 60% of the liver of a normal person produces minimal and transient hepatic impairment
- ▣ Regeneration restores most of the liver mass within 4 to 6 weeks.

Regeneration

- ▣ *Regeneration.*
- ▣ Cell death or tissue resection (such as in living-donor transplantation) triggers hepatocyte replication, to compensate for the cell or tissue loss.
- ▣ *It is a normal compensatory response to cell death*

It is common

-1/3 OF THE WORLD POPULATION
EXPOSED TO VIRAL HEPATITIS B

-The global prevalence of HBV infection in the general population was estimated at 3.5% with about 257 million persons living with chronic HBV infection.

<http://www.who.int/wer>

Position paper WHO2017


More than one million of Syrian population are infected by hepatitis B&C

Winning over ---

Therapeutic endoscopy

largely replaced surgery for

- Gastrointestinal bleeding
- Tumor palliation
- Biliary diseases.



© 2009 Terese W
U.S. Govt. has certa

4 ABDOMINAL EXAMINATION: POSSIBLE FINDINGS

Hepatomegaly
Palpable gallbladder


(Ch. 23)

Epigastric mass

Gastric cancer
Pancreatic cancer
Aortic aneurysm

Left upper quadrant mass

<i>?Spleen</i>	<i>?Kidney</i>
Edge	Rounded
Can't get above it	Can get above it
Moves towards right iliac fossa	Moves down
Dull percussion note	Resonant to percussion
Notch	Ballotable



Tender to palpation

<i>?Peritonitis</i>	<i>?Obstruction</i>
Guarding and rebound	Distended
Absent bowel sounds	Tinkling bowel sounds
Rigidity	Visible peristalsis

Left iliac fossa mass

Sigmoid colon cancer
Constipation
Diverticular mass

Generalised distension

Fat (obesity)
Fluid (ascites)
Flatus (obstruction/ileus)
Faeces (constipation)
Fetus (pregnancy)

Right iliac fossa mass

Caecal carcinoma
Crohn's disease
Appendix abscess

Suprapubic mass


Bladder
Pregnancy
Fibroids/carcinoma



5 PALPATION OF THE ABDOMEN

Liver


- Start in the right iliac fossa.
- Progress up the abdomen 2 cm with each breath (through open mouth)
- Confirm the lower border of the liver by percussion (see 6).



- Detect if smooth or irregular, tender or non-tender; ascertain shape.
- Identify the upper border by percussion (see 6).

Spleen

- Start again in the right iliac fossa.
- Progress towards the left upper quadrant at 2 cm intervals.
- Place the left hand around the lower lateral ribs as the costal margin is approached.



- Note the characteristics of the spleen
 - Notch
 - Superficial
 - Dull to percussion
 - Cannot get between ribs and spleen
 - Moves well with respiration

Nutrient metabolism

Carbohydrate
Protein
Lipids

Protein synthesis

Albumin
Coagulation factors
Complement factors
Haptoglobin
Caeruloplasmin
Transferrin
Protease inhibitors

Storage

Iron
Copper
Vitamins A, D and B₁₂

Excretion

Bile salts
Bilirubin

© Elsevier. Boon et al.: Davidson's Principles and Practice of Medicine 20e - www.studentconsult.com

Main liver Functions

What does the liver do?

500 VITAL FUNCTIONS

Immunity
against infection

Regulates blood
clotting


Factory for proteins
and cholesterol

Clears blood of drugs,
Chemicals, alcohol


Excretes wastes via bile


Converts excess glucose
to starch for storage

Excretes bile for fat digestion



LIVER FUNCTIONS





1. Metabolism&Production

A. Amino acids are either used for the production of plasma proteins...:

1. Albumin 8-14 mg/day is necessary for maintaining vascular oncotic pressure and transporting small molecules eg. bilirubin
2. Clotting factors (II,VII,IX,X) which are in turn modified by vitamin K-dependent enzymes (Vit K is also stored in the liver)
3. Complement factors
4. Haptoglobin (bind to the free hemoglobin in the blood)
5. Transferrin (iron carrier in the blood)
6. Protease inhibitors: eg. alpha1-antitrypsin

... The remaining Amino Acids are broken down to urea

B. $\frac{1}{2}$ of the absorbed Glucose is:

1. stored in the liver as Glycogen or converted to glycerol & fatty acids (thus preventing hyperglycemia).
2. During fasting gluconeogenesis occurs to prevent hypoglycemia.

C. Liver metabolize lipids: producing very low-density lipoproteins & also metabolize low and high density lipoproteins.

D. Bilirubin metabolism: conjugation bilirubin into bilirubin mono or di -glucuronide by the enzyme UDP-glucuronyl transferase.

E. Drugs absorbed from the gut by the portal vein reach the liver to be metabolized, sometimes into other forms (some are even more effective), and after the drug does its action its mostly metabolized into inert compounds.


Storage

- 1. Vitamin A,D and B12 are stored in large amounts.
- 2. Vitamin K & folate in smaller amounts.
- 3. Iron within 2 compounds (ferritin&hemosiderin)
- 4.copper (also excreted in bile)


Excretion

- The main excreted product is the Bile which contains:
 1. Bile acids (from cholesterol)
 2. Bilirubin (conjugated)
 3. phospholipids
 4. cholesterol
 5. copper
 6. Drugs
 7. Nutrient metabolism waste products


Immune regulation




- 9% of normal liver is immune cells.
 1. Cells for Innate immunity:
 - 4% Kupffer cells (from blood monocytes)
 - 2.5% Macrophages & Natural killer cells
 2. Cells for adaptive immunity: B&T lymphocytes



© Elsevier. Boon et al.: Davidson's Principles and Practice of Medicine 20e - www.studentconsult.com






liver from to

healthy



cirrhosis








Edema (swelling) of the ankles and feet




Figure 10. Photograph shows a caput medusae accentuated by a large amount of ascites in a patient being prepared for liver transplantation.



Henseler K P et al. Radiographics 2001;21:691-704

RadioGraphics



© Elsevier. Boon et al.: Davidson's Principles and Practice of Medicine 20e - www.studentconsult.com


Jaundice




Jaundice is usually detectable clinically when the plasma bilirubin exceeds $40 \mu\text{mol/L}$ ($\sim 2.5 \text{ mg/dL}$).

Manifestations



- Liver injury and its manifestations tend to follow characteristic morphologic and clinical patterns, regardless of cause.



Multidisciplinary approach !




**Patient Chart
& imaging**



Bilirubin

The breakdown product of haem
 the body usually produces about 300mg of bilirubin
 Iron is removed from the haem molecule and the porphyrin ring is
 opened to form bilirubin

Bilirubin



Bilirubin

Direct: water soluble

Indirect: lipid soluble

Red blood cells

Ineffective erythropoiesis


Other haem protein such as myoglobin and cytochromes

80%

20%

Transport in plasma and hepatic up take

In plasma
((bilirubin bound to albumin))



Not filtered at
the glomerulus
unless there is
glomerular proteinuria

On reaching the liver the bilirubin is taken
into the hepatocyte

unconjugated bilirubin


=

Most of Plasma bilirubin

Conjugation of bilirubin

Endoplasmic reticulum of hepatocyte

Bilirubin + glucuronic acid



bilirubin glucuronides
“conjugated bilirubin”
“Water soluble and readily
transported into bile”

Bilirubin glucuronides (CONJUGATED BILIRUBIN)
cant be reabsorbed from the gut

degraded by
bacterial action
mainly in the
colon

Urobilinogen
mixture of colorless,
water soluble
compounds

OXIDISE

**UROBILINS
AND
STERCIBILINS**
"Brown"

Excreted in faeces


A small percentage
of urobilinogen
undergoes
enterohepatic
circulation

Most of it
is cleared
by the
liver

Proportion filtered at
the kidney and appears
in the urine

	Urine tests	
Condition	Urobilinogen	bilirubin
Healthy individuals	Trace	Nil
Gilbert's syndrome	Trace	Nil
Haemolytic disease	Increased	Nil
Hepatitis •prodormal •icteric stage	Increased Undetectable	detectable present
Biliary obstruction	Undetectable	present

Syndrome	Inheritance	Abnormality	Clinical features/treatment
Unconjugated hyperbilirubinaemia			
Gilbert's	Autosomal dominant	↓ Glucuronyl transferase ↓ Bilirubin uptake	Mild jaundice, especially with fasting No treatment necessary
Crigler–Najjar			
Type I	Autosomal recessive	Absent glucuronyl transferase	Rapid death in neonate (kernicterus)
Type II	Autosomal dominant	↓↓ Glucuronyl transferase	Presents in neonate Phenobarbital, ultraviolet light or liver transplant as treatment
Conjugated hyperbilirubinaemia			
Dubin–Johnson	Autosomal recessive	↓ Canalicular excretion of organic anions, including bilirubin	Mild No treatment necessary
Rotor's	Autosomal recessive	↓ Bilirubin uptake ↓ Intrahepatic binding	Mild No treatment necessary



Abnormal alkaline phosphatase or serum transaminases < 2 upper limit of normal

- Alcohol abstinence
- Stop hepatotoxic drugs
- Advise weight loss if BMI > 25
- Check GGT if raised alkaline phosphatase
- Recheck LFT in 3-6 months

Persistently abnormal LFT

Abnormal alkaline phosphatase or serum transaminases > 2 upper limit of normal


Liver screen ie fully history chronic liver disease screen
 Ultrasound abdomen
 HBsAg
 HCVAb
 @1-AT
 Autoimmune profile
 Ferritin
 Caeruloplasmin immunoglobulin

Dilated Bile duct

Cholangiography MRCP or ERCP

Non-dilated bile duct


Consider liver biopsy and treat underlying disorder



What is jaundice?

- ▶ yellowish pigmentation of the
- ▶ skin, the sclera, and other mucous membranes

- ▶ Jaundice is usually detectable clinically when the plasma bilirubin exceeds $50 \mu\text{mol/L}$



Hepatocellular jaundice

Both unconjugated and conjugated bilirubin in the blood increase!!!

Hepatocellular jaundice

results from an inability of the liver to transport bilirubin into the bile, as a consequence of parenchymal liver disease. ▶

INABILITY TO SECRETE BILE CHOLESTASIS

Cholestatic jaundice may be caused by:

- Failure of hepatocytes to initiate bile flow.
- Obstruction of the bile ducts or portal tracts.
- Obstruction of bile flow in the extrahepatic bile ducts.

BILE

The only way in which we can get rid of cholesterol and copper from the body

Enterohepatic circulation 90% of bile is re absorbed

Causes of
jaundice

Pre- hepatic

hepatic

Post-hepatic

PRE-HEPATIC JAUNDICE

This is caused either by ✕
1-Haemolysis or
2-congenital hyperbilirubinaemia,
and is characterised by an
isolated raised bilirubin level.

PRE-HEPATIC JAUNDICE

bilirubin load six times greater than normal before unconjugated bilirubin accumulates in the plasma.

- ▶ This does not apply to the newborn, who have a reduced capacity to metabolise bilirubin.

Liver function tests

serum bilirubin

Aminotransferases ALT/AST

Alkaline phosphatase

Gama-glutamyl transferase GGT

Albumin

Prothrombin time (INR)

HEPATIC SYNTHETIC FUNCTION

PT

Albumin


PT

Assess hepatic function

Involves factor II, V, VII, and X, synthesized by the liver

Albumin 8-14g/day

Half-life is 20 days



Aminotransferase

Amino transferase: -ALT ▶
-AST

Both transfer amino group from amino acid to ketoacid producing pyruvate and oxaloacetate

Tests of hepatic function

Serum albumin

Serum bilirubin

Prothrombin

Tests of hepatocellular injury or cholestasis

Aminotransferase

Alkaline phosphatase

Gama-glutamyl transferase

Common causes of elevated serum transaminases

Minor elevation (< 100 U/L)

- Chronic hepatitis C
- Chronic hepatitis B
- Haemochromatosis
- Fatty liver disease

Moderate elevation (100–300 U/L)

As above plus:

- Alcoholic hepatitis
- Non-alcoholic steatohepatitis
- Autoimmune hepatitis
- Wilson's disease

Major elevation (> 300 U/L)

- Drugs (e.g. paracetamol)
- Acute viral hepatitis
- Autoimmune liver disease
- Ischaemic liver
- Toxins (e.g. *Amanita phalloides* poisoning)
- Flare of chronic hepatitis B



تكشف اضطرابات الكبد عادة أثناء اجراء فحص دموي روتيني
(مثلاً: يظهر ارتفاع بخمائر الكبد لدى 3.5 % من المرضى الذين
يتحضرون لعمل جراحي).
يوجد مرض كبدي ما عند أغلب المرضى الذين لديهم ارتفاع مستمر بهذه
القيم

GGT:

Microsomal enzyme

transfer glutamyl groups from gama-glutamyl peptides to other peptides and amino acid

GGT

Alcohol use

BMI

Anticonvulsant

Warfarin

Age gender

Smoking



Alkaline phosphatase

Enzymes Are capable of hydrolysing phosphatases at alkaline PH

Bilirubin glucuronides (CONJUGATED BILIRUBIN)

can't be reabsorbed from the gut

degraded by
bacterial
action
mainly in
the colon

OXIDISE

STERCIBILINS

Excreted in faeces
"Brown"

LIVER AND COAGULATION

	clotting	Anti-clotting
Vitamin k dependent	II VII IX X	Protein C protein S
independent of Vit K	I V Viii	Antithrombin III

COAGULATION PROTEINS /BALANCING CF



IMPORTANT

the presence or absence of stigmata of chronic liver disease

does not reliably identify patients with significant chronic liver disease.

The absence of these stigmata should not therefore preclude further investigation

Clinical situation

action

management

Increased bilirubin only

Recheck with conjugated bilirubin exclude haemolysis

Reassure as likely Gilbert syndrome


Increased GGT only

Determine whether:
Alcohol excess
Enzyme induction from drug
High BMI


Alcohol abstinence

No action

Lose weight




Hepatitis Mortality is increasing 2000-2015



**By the year 2030:
20 million new deaths will occur if No Action is going to be undertaken**

The course of HCV infection with no treatment



Serologic Diagnosis of Acute Hepatitis

DIAGNOSIS	SCREENING ASSAYS	SUPPLEMENTAL ASSAYS
Hepatitis A	IgM anti-HAV	None needed
Hepatitis B	HBsAg, IgM anti-HBc	HBeAg, anti-HBe HBV DNA
Hepatitis C	Anti-HCV by EIA	HCV RNA by PCR; anti-HCV by Immunoblot
Hepatitis D	HBsAg	Anti-HDV
Hepatitis E	History	Anti-HEV
Mononucleosis	History, white blood cell differential counts	Monospot test Heterophil antibody
Drug-induced hepatitis	History	

	Hepatitis B	Hepatitis C	Hepatitis D
Virus			
Spread			
Faeces	No	No	No
Blood	Yes	Yes	Yes
Saliva	Yes	Yes	?
Sexual	Yes	Uncommon	Yes
Vertical	Yes	Uncommon	Yes
Chronic infection	Yes	Yes	Yes
Prevention			
Active	Vaccine	No	Prevented by
Passive	Hyperimmune immunoglobulin	No	<u>hepatitis B vaccine</u>

Route of transmission	Risk of chronic infection
Horizontal transmission	10%
Injection drug use	
Infected unscreened blood products	
Tattoos/acupuncture needles	
Sexual (homosexual and heterosexual)	
Vertical transmission	90%
HbsAg-positive mother	

Global Burden of Viral Hepatitis (Estimates)

- 2000 million (2 billion) infected with hepatitis B (> 350 million chronically)
- 130–170 million chronically infected with hepatitis C
- 57% of liver cirrhosis and 78% of primary liver cancer due to hepatitis B or C
- ~600,000 deaths annually – hepatitis B
- > 350,000 deaths annually – hepatitis C
- 2.7% all deaths due to acute hepatitis B and C, cancer/ cirrhosis of liver (increasing over time)

Hepatitis C prevalence in people who inject drugs

People who inject drugs – the most affected population group

Prevalence estimates

30% to 98% in EU countries (2002)

21% to 86% in 9 EU countries (2012)

Sources: Roy K, et al 2002. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. *Epidemiology & Infection*. 129: 577-85; Rony M, et al 2012. Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting. *Epidemiology & Infection*

Liver biopsy


Why?

a liver biopsy is often required to stage the •
degree of liver damage.


scoring system

- The most common scoring system used is the Metavir system,
- which scores fibrosis from 1 to 4, the
- latter equating to cirrhosis


What is a Liver Biopsy?



A small slender core of tissue is removed with a biopsy needle



ADAM.



Laparoscopic technique



Laparoscopic needle biopsy © Elsevier, Inc. - Netterimages.com Laparoscopic excision biopsy

© ELSEVIER, INC. - NETTERIMAGES.COM